Grace Therapeutics, Inc. (GRCE) stock
GRCENasdaqPharmaceutical PreparationsFiscal year ends March 31
$1.81−0.04 (-2.43%)
Close on Nov 12, 2026Market cap $38.08MP/E –Yield –
Grace Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Grace Therapeutics's enterprise value was $16.43M on Nov 11, 2026, against $43.04M a year earlier. Over the last 5 years it ranged from -$23.50M to $52.97M, with a median of $15.91M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $16.43M | -65.0% |
| 2025 | Dec 31, 2025 | $46.99M | +13.4% |
| 2024 | Dec 31, 2024 | $41.45M | +276.7% |
| 2023 | Dec 29, 2023 | $11.00M | – |
| 2022 | Dec 30, 2022 | -$9.49M | – |
| 2021 | Dec 31, 2021 | -$20.89M | -187.6% |
| 2020 | Dec 31, 2020 | $23.84M | +154.0% |
| 2019 | Apr 30, 2019 | $9.39M | +4.6% |
| 2018 | Dec 31, 2018 | $8.97M | -11.8% |
| 2017 | Dec 29, 2017 | $10.17M | -23.7% |
| 2016 | Dec 30, 2016 | $13.32M | – |
See a number that looks wrong?